HomeCompareAQUA vs ABBV

AQUA vs ABBV: Dividend Comparison 2026

AQUA yields 4.01% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ABBV wins by $76.4K in total portfolio value
10 years
AQUA
AQUA
● Live price
4.01%
Share price
$49.88
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$26.0K
Annual income
$518.67
Full AQUA calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — AQUA vs ABBV

📍 ABBV pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodAQUAABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, AQUA + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
AQUA pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

AQUA
Annual income on $10K today (after 15% tax)
$340.82/yr
After 10yr DRIP, annual income (after tax)
$440.87/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, ABBV beats the other by $20,615.14/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of AQUA + ABBV for your $10,000?

AQUA: 50%ABBV: 50%
100% ABBV50/50100% AQUA
Portfolio after 10yr
$64.2K
Annual income
$12,645.22/yr
Blended yield
19.71%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

AQUA
Analyst Ratings
6
Buy
9
Hold
Consensus: Hold
Price Target
$50.50
+1.2% upside vs current
Range: $50.00 — $52.00
Altman Z
3.9
Piotroski
7/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

AQUA buys
0
ABBV buys
0
No recent congressional trades found for AQUA or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricAQUAABBV
Forward yield4.01%3.06%
Annual dividend / share$2.00$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%40.6%
Portfolio after 10y$26.0K$102.3K
Annual income after 10y$518.67$24,771.77
Total dividends collected$4.6K$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare
Analyst consensusHoldBuy
Analyst price target$50.50$256.15

Year-by-year: AQUA vs ABBV ($10,000, DRIP)

YearAQUA PortfolioAQUA Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$11,101$400.96$11,550$430.00$449.00ABBV
2$12,294$415.99$13,472$627.96$1.2KABBV
3$13,585$430.56$15,906$926.08$2.3KABBV
4$14,981$444.65$19,071$1,382.55$4.1KABBV
5$16,488$458.25$23,302$2,095.81$6.8KABBV
6$18,113$471.35$29,150$3,237.93$11.0KABBV
7$19,865$483.94$37,536$5,121.41$17.7KABBV
8$21,752$496.03$50,079$8,338.38$28.3KABBV
9$23,782$507.60$69,753$14,065.80$46.0KABBV
10$25,965$518.67$102,337$24,771.77$76.4KABBV

AQUA vs ABBV: Complete Analysis 2026

AQUAStock

Evoqua Water Technologies Corp. provides water and wastewater treatment systems and technologies, and mobile and emergency water supply solutions and contract services for industrial, commercial, and municipal water treatment markets in the United States and internationally. It operates in two segments, Integrated Solutions and Services, and Applied Product Technologies. The Integrated Solutions and Services segment offers capital systems and related recurring aftermarket services, parts, and consumables, as well as long-term and short-term service contracts, and emergency services for treating process water, utility water, and wastewater. This segment also provides odor and corrosion control services and drinking water treatment systems for municipalities. It serves manufacturing, healthcare, pharmaceuticals, biotech, power, microelectronics, chemical processing, food and beverage, and refining industries. The Applied Product Technologies segment offers advanced filtration and separation products, such as VAF self-cleaning filters, Ionpure electrodeionization systems, and Vortisand filtration systems, as well as filter presses and related consumables, and aftermarket products for customers in the microelectronics, pharmaceutical, and power end markets. It also offers disinfection solutions, including chemical and non-chemical disinfection technologies comprising low and medium pressure ultraviolet, ozone, onsite hypochlorite generation, and chlorine and chlorine dioxide systems for municipal drinking water, industrial, light manufacturing, commercial, and aquatics markets. In addition, this segment offers wastewater technologies, including biological treatment, clarification, filtration, nutrient removal, biosolid, and field-erected biological wastewater treatment plant solutions. Further, it offers aquatics and electrochlorination solutions. The company was incorporated in 2013 and is headquartered in Pittsburgh, Pennsylvania.

Full AQUA Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this AQUA vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

AQUA vs SCHDAQUA vs JEPIAQUA vs OAQUA vs KOAQUA vs MAINAQUA vs JNJAQUA vs MRKAQUA vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.